3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
100
Carcinoma, Non-Small-Cell Lung
48
Neoplasms
34
Urinary Bladder Neoplasms
25
Lung Neoplasms
25
Cholangiocarcinoma
23
Breast Neoplasms
22
Neoplasm Metastasis
21
Ovarian Neoplasms
18
Lymphoma, Non-Hodgkin
13
Lymphoma
13
Recurrence
12
Lymphoma, Large B-Cell, Diffuse
11
Biliary Tract Neoplasms
11
Sarcoma
10
Carcinoma, Transitional Cell
9
Hodgkin Disease
8
Gallbladder Neoplasms
8
Fallopian Tube Neoplasms
8
Adenocarcinoma
8
Bile Duct Neoplasms
7
Colorectal Neoplasms
6
Triple Negative Breast Neoplasms
5
Lymphoma, Follicular
5
Liver Neoplasms
5
Head and Neck Neoplasms
5
Carcinoma, Renal Cell
5
Adenocarcinoma of Lung
5
Uterine Cervical Neoplasms
4
Small Cell Lung Carcinoma
4
Interventions
umbralisib
1
ublituximab
1
marizomib
1
fludarabine phosphate
1
fludarabine
1
enzastaurin
1
durvalumab
1
carotuximab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
Zoledronic Acid
1
Vitamin D
1
Receptors, Interleukin-6
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Interleukin 1 Receptor Antagonist Protein
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cyclophosphamide
1
Cisplatin
1
Calcium
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Disease Progression
×
Gemcitabine
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts